ClinicalTrials.gg
CompletedNCT05459571ZUMA-24Updated Nov 12, 2026Results posted

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

A Phase 2 interventional study of Axicabtagene Ciloleucel and Cyclophosphamide in Relapsed or Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study was to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.

Read the detailed description

Participants who completed at minimum 18 months follow up were transitioned to a separate long-term follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.

02

Conditions studied

  • Relapsed or Refractory Large B-cell Lymphoma

Browse trials for

03

In context

Lead sponsor

Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

First submitted after Kite became part of Gilead Sciences.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed large B-cell lymphoma (LBCL), including the following types defined by World Health Organization (WHO) 2016 classification, by local pathology laboratory assessment, are eligible as defined below:

    • Diffuse large B-cell lymphoma (DLBCL) not otherwise specified.
    • High-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 and/or BCL6 rearrangement.
    • DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV) + DLBCL.
    • Primary mediastinal (thymic) LBCL.
    • Primary cutaneous DLBCL, leg type.
    • Transformation of follicular lymphoma to DLBCL will also be included.
  • disease after 1 or more .
  • Individuals must have received adequate prior therapy including:

    • Anti-CD20 monoclonal antibody AND
    • An anthracycline-containing chemotherapy regimen.
  • At least 1 according to the Lugano Response Criteria for Malignant Lymphoma. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
  • (ECOG) performance status of 0 or 1.
  • Individual agrees to outpatient treatment setting and to adhere to the prespecified clinical monitoring requirements.

Key Exclusion Criteria:

  • History of or allogeneic stem cell transplant.
  • Prior cluster of differentiation (CD)19 targeted therapy.
  • Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite medical monitor.
  • Individuals with detectable cerebrospinal fluid malignant cells, , or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma. DLBCL epidural involvement should be considered as positive CNS disease.
  • In the investigator's judgment, the individual is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Axicabtagene Ciloleucel

    Participants will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m\^2/day and fludarabine 30 mg/m\^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2. Participants will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10\^6 cells/kg.

    Biological: Axicabtagene Ciloleucel · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity

    CRS were identified via collection of the syndrome on a case report form specifically designed to collect CRS. Individual symptoms of CRS were separately collected on the Adverse Event (AE) log and were linked to the CRS syndrome. CRS events were graded per the revised grading system proposed by Lee et al 2014. Grade 1: Symptoms are not life threatening and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms; Grade 5: Death.

    Time frame: Up to 2.2 years

  2. Percentage of Participants With Treatment-emergent Neurologic Events as Per Severity

    Neurological events were identified with a search strategy based on known neurologic toxicities associated with anti-CD19 immunotherapy. The search strategy focused on central nervous system toxicity, without regard to temporal relationship and concomitant conditions. Neurologic events were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening consequences, Grade 5: Death.

    Time frame: Up to 2.2 years

Secondary outcomes

  1. Time to Onset of CRS Following Axicabtagene Ciloleucel Administration

    Time to onset was defined as the earliest start date of CRS minus the axicabtagene ciloleucel infusion date plus 1. Participants without CRS by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. Kaplan-Meier (KM) estimates was used for analyses.

    Time frame: Up to 2.2 years

  2. Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration

    Time to onset was defined as the earliest start date of neurologic event minus the axicabtagene ciloleucel infusion date plus 1. Participants without neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.

    Time frame: Up to 2.2 years

  3. Duration of CRS Following Axicabtagene Ciloleucel Administration

    Duration was defined as the latest end date of CRS minus the start date of the earliest CRS plus 1. Participants with unresolved or ongoing CRS by the data cutoff were censored at death date if participant died or last known alive date if participant is still alive; participants who withdrew consent, were censored at end of study date. KM estimates was used for analyses.

    Time frame: Up to 2.2 years

  4. Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration

    Duration was defined as the latest end date of neurologic event minus the start date of the earliest neurologic event plus 1. Participants with unresolved or ongoing neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.

    Time frame: Up to 2.2 years

  5. Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion

    Hospitalized within 72 hours refers to 72 hours from the time when axicabtagene ciloleucel infusion starts.

    Time frame: Within 72 hours of axicabtagene ciloleucel infusion on Day 0

  6. Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion

    Hospitalization within 4 days refers to the period from Day 0 to Day 3 following axicabtagene ciloleucel infusion.

    Time frame: Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)

  7. Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion

    Hospitalization within 7 days refers to the period from Day 0 to Day 6 following axicabtagene ciloleucel infusion.

    Time frame: Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)

  8. Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion

    Hospitalization within 14 days refers to the period from Day 0 to Day 13 following axicabtagene ciloleucel infusion.

    Time frame: Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)

  9. Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion

    Hospitalization within 30 days refers to the period from Day 0 to Day 29 following axicabtagene ciloleucel infusion.

    Time frame: Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)

  10. Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion

    Time frame: Up to 2.2 years

  11. Percentage of Intensive Care Unit (ICU) Admitted Participants

    Time frame: Up to 30 days

  12. Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion

    Time frame: Up to 2.2 years

  13. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. TEAEs were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion.

    Time frame: Up to 2.2 years

  14. Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)

    A serious adverse event (SAEs) was defined as an event that, at any dose, resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. TESAEs were defined as any serious adverse event with onset on or after the axicabtagene ciloleucel infusion.

    Time frame: Up to 2.2 years

  15. Number of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score

    The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).

    Time frame: Baseline, Week 4, Month 3, Month 6

  16. EQ-5D-5L Visual Analogue Scale (EQ-VAS) Score

    The EQ-VAS is a vertical VAS for recording self-rated current Health-Related Quality of Life (HRQoL) state reported from 0, described as "the worst health you can imagine", to 100, described as "the best health you can imagine" Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).

    Time frame: Baseline, Week 4, Month 3, Month 6

  17. Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

    OR: complete response (complete metabolic response\[CMR\]; complete radiologic response\[CRR\]) or partial response (partial MR \[PMR\]; partial RR \[PRR\]). CMR: positron emission tomography(PET) 5-point scale(5-PS) of 1-3 with/without residual mass; no new sites/evidence of fluorodeoxyglucose(FDG)-avid disease in bone marrow(BM).CRR: target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter(LDi) of lesion;no extra lymphatic sites;absent nonmeasured lesion(NMLs);organ enlargement regress to normal;no new sites;BM normal by morphology.PMR:5PS scores 4/5 with reduced uptake compared to baseline,residual masses of any size;no new sites;residual uptake higher than uptake in normal BM,reduced compared with baseline.PRR:≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes \& extranodal sites;absent/normal,regressed but no increase of NMLs;spleen regressed by \>50%;no new sites of disease. 95% CI were calculated by Clopper-Pearson method.

    Time frame: Up to 2.5 years

  18. Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

    Complete response is defined as participants with CMR and CRR. CMR: PET 5-PS scores of 1-3 with or without residual mass; no new sites/evidence of FDG-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5cm in LDi of lesion; no extra lymphatic sites; absent NMLs; organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% CI were calculated by Clopper-Pearson method. Percentages were rounded off.

    Time frame: Up to 2.5 years

  19. Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

    DOR is the time from first OR to disease progression (PD) or death from any cause. OR is defined in outcome measure (OM) 19. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

    Time frame: Up to 2.5 years

  20. Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

    PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression or, if no disease progression, the date of death due to any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

    Time frame: Up to 2.5 years

  21. Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

    EFS is defined as the time from axicabtagene ciloleucel infusion to the earliest date of disease progression, commencement of new anti-lymphoma therapy (excluding SCT), or death from any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

    Time frame: Up to 2.5 years

  22. Overall Survival (OS)

    OS was defined as the time from the axicabtagene ciloleucel infusion date to the date of death from any cause. KM estimates was used for analyses.

    Time frame: Up to 2.5 years

  23. Peak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15

    Peak is defined as the maximum analyte level in blood measured after infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  24. Peak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  25. Peak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  26. Peak Serum Levels of Immune Effector Molecules: Perforin

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  27. Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  28. Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  29. Peak Serum Levels of the Acute Phase Response Proteins: Ferritin

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  30. Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  31. Peak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)

    Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

    Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

  32. Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells

    Peak is defined as the maximum number of CAR T-cells in blood measured after axicabtagene ciloleucel infusion.

    Time frame: Up to 24 months

07

Results

Posted Nov 12, 2026

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneAxicabtagene Ciloleucel
Started35
Completed0
Not completed35
Withdrew: Transition to the kt-us-982-5968 study19
Withdrew: Death9
Withdrew: Subject full withdrawal of consent from further follow-up3
Withdrew: Investigator decision2
Withdrew: Deep vein thrombosis1
Withdrew: Expired cells1

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity

CRS were identified via collection of the syndrome on a case report form specifically designed to collect CRS. Individual symptoms of CRS were separately collected on the Adverse Event (AE) log and were linked to the CRS syndrome. CRS events were graded per the revised grading system proposed by Lee et al 2014. Grade 1: Symptoms are not life threatening and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms; Grade 5: Death.

Time frame:
Up to 2.2 years
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity
percentage of participantsAxicabtagene Ciloleucel
Worst Grade 137
Worst Grade 253
Worst Grade 30
Worst Grade 40
Worst Grade 50
PrimaryPercentage of Participants With Treatment-emergent Neurologic Events as Per Severity

Neurological events were identified with a search strategy based on known neurologic toxicities associated with anti-CD19 immunotherapy. The search strategy focused on central nervous system toxicity, without regard to temporal relationship and concomitant conditions. Neurologic events were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening consequences, Grade 5: Death.

Time frame:
Up to 2.2 years
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Neurologic Events as Per Severity
percentage of participantsAxicabtagene Ciloleucel
Worst Grade 130
Worst Grade 227
Worst Grade 320
Worst Grade 43
Worst Grade 50
SecondaryTime to Onset of CRS Following Axicabtagene Ciloleucel Administration

Time to onset was defined as the earliest start date of CRS minus the axicabtagene ciloleucel infusion date plus 1. Participants without CRS by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. Kaplan-Meier (KM) estimates was used for analyses.

Time frame:
Up to 2.2 years
Reported as:
Median · days
Time to Onset of CRS Following Axicabtagene Ciloleucel Administration
daysAxicabtagene Ciloleucel
Time to Onset of CRS Following Axicabtagene Ciloleucel Administration4.0 (NA to NA)
SecondaryTime to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration

Time to onset was defined as the earliest start date of neurologic event minus the axicabtagene ciloleucel infusion date plus 1. Participants without neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.

Time frame:
Up to 2.2 years
Reported as:
Median · days
Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration
daysAxicabtagene Ciloleucel
Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration7.0 (6.0 to 14.0)
SecondaryDuration of CRS Following Axicabtagene Ciloleucel Administration

Duration was defined as the latest end date of CRS minus the start date of the earliest CRS plus 1. Participants with unresolved or ongoing CRS by the data cutoff were censored at death date if participant died or last known alive date if participant is still alive; participants who withdrew consent, were censored at end of study date. KM estimates was used for analyses.

Time frame:
Up to 2.2 years
Reported as:
Median · days
Duration of CRS Following Axicabtagene Ciloleucel Administration
daysAxicabtagene Ciloleucel
Duration of CRS Following Axicabtagene Ciloleucel Administration5.0 (3.0 to 6.0)
SecondaryDuration of Neurologic Events Following Axicabtagene Ciloleucel Administration

Duration was defined as the latest end date of neurologic event minus the start date of the earliest neurologic event plus 1. Participants with unresolved or ongoing neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.

Time frame:
Up to 2.2 years
Reported as:
Median · days
Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration
daysAxicabtagene Ciloleucel
Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration5.5 (3.0 to 46.0)
SecondaryPercentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion

Hospitalized within 72 hours refers to 72 hours from the time when axicabtagene ciloleucel infusion starts.

Time frame:
Within 72 hours of axicabtagene ciloleucel infusion on Day 0
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion37
SecondaryPercentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion

Hospitalization within 4 days refers to the period from Day 0 to Day 3 following axicabtagene ciloleucel infusion.

Time frame:
Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion63
SecondaryPercentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion

Hospitalization within 7 days refers to the period from Day 0 to Day 6 following axicabtagene ciloleucel infusion.

Time frame:
Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion90
SecondaryPercentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion

Hospitalization within 14 days refers to the period from Day 0 to Day 13 following axicabtagene ciloleucel infusion.

Time frame:
Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion93
SecondaryPercentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion

Hospitalization within 30 days refers to the period from Day 0 to Day 29 following axicabtagene ciloleucel infusion.

Time frame:
Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion93
SecondaryDuration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion
Time frame:
Up to 2.2 years
Reported as:
Median · days
Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion
daysAxicabtagene Ciloleucel
Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion8 (2 to 44)
SecondaryPercentage of Intensive Care Unit (ICU) Admitted Participants
Time frame:
Up to 30 days
Reported as:
Number · percentage of participants
Percentage of Intensive Care Unit (ICU) Admitted Participants
percentage of participantsAxicabtagene Ciloleucel
Admitted to ICU at any time13
Admitted to ICU within 72 hours7
Admitted to ICU within 4 days7
Admitted to ICU within 7 days10
Admitted to ICU within 14 days13
Admitted to ICU within 30 days13
SecondaryDuration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion
Time frame:
Up to 2.2 years
Reported as:
Median · days
Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion
daysAxicabtagene Ciloleucel
Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion7 (2 to 7)
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. TEAEs were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion.

Time frame:
Up to 2.2 years
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)100
SecondaryPercentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)

A serious adverse event (SAEs) was defined as an event that, at any dose, resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. TESAEs were defined as any serious adverse event with onset on or after the axicabtagene ciloleucel infusion.

Time frame:
Up to 2.2 years
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)80
SecondaryNumber of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score

The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).

Time frame:
Baseline, Week 4, Month 3, Month 6
Reported as:
Count of participants · Participants
Number of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score
ParticipantsAxicabtagene Ciloleucel
Mobility: Baseline — No problems16
Mobility: Baseline — Slight problems7
Mobility: Baseline — Moderate problems1
Mobility: Baseline — Severe problems0
Mobility: Baseline — Extreme problems0
Mobility: Week 4 — No problems15
Mobility: Week 4 — Slight problems6
Mobility: Week 4 — Moderate problems2
Mobility: Week 4 — Severe problems1
Mobility: Week 4 — Extreme problems0
Mobility: Month 3 — No problems14
Mobility: Month 3 — Slight problems4
Mobility: Month 3 — Moderate problems3
Mobility: Month 3 — Severe problems0
Mobility: Month 3 — Extreme problems0
Mobility: Month 6 — No problems12
Mobility: Month 6 — Slight problems6
Mobility: Month 6 — Moderate problems0
Mobility: Month 6 — Severe problems0
Mobility: Month 6 — Extreme problems0
Self-Care: Baseline — No problems22
Self-Care: Baseline — Slight problems1
Self-Care: Baseline — Moderate problems1
Self-Care: Baseline — Severe problems0
Self-Care: Baseline — Extreme problems0
Self-Care: Week 4 — No problems18
Self-Care: Week 4 — Slight problems5
Self-Care: Week 4 — Moderate problems0
Self-Care: Week 4 — Severe problems1
Self-Care: Week 4 — Extreme problems0
Self-Care: Month 3 — No problems18
Self-Care: Month 3 — Slight problems2
Self-Care: Month 3 — Moderate problems1
Self-Care: Month 3 — Severe problems0
Self-Care: Month 3 — Extreme problems0
Self-Care: Month 6 — No problems15
Self-Care: Month 6 — Slight problems3
Self-Care: Month 6 — Moderate problems0
Self-Care: Month 6 — Severe problems0
Self-Care: Month 6 — Extreme problems0
Usual Activity: Baseline — No problems16
Usual Activity: Baseline — Slight problems6
Usual Activity: Baseline — Moderate problems1
Usual Activity: Baseline — Severe problems1
Usual Activity: Baseline — Extreme problems0
Usual Activity: Week 4 — No problems10
Usual Activity: Week 4 — Slight problems6
Usual Activity: Week 4 — Moderate problems4
Usual Activity: Week 4 — Severe problems3
Usual Activity: Week 4 — Extreme problems1
Usual Activity: Month 3 — No problems8
Usual Activity: Month 3 — Slight problems6
Usual Activity: Month 3 — Moderate problems5
Usual Activity: Month 3 — Severe problems2
Usual Activity: Month 3 — Extreme problems0
Usual Activity: Month 6 — No problems12
Usual Activity: Month 6 — Slight problems4
Usual Activity: Month 6 — Moderate problems2
Usual Activity: Month 6 — Severe problems0
Usual Activity: Month 6 — Extreme problems0
Pain / Discomfort: Baseline — No problems12
Pain / Discomfort: Baseline — Slight problems8
Pain / Discomfort: Baseline — Moderate problems2
Pain / Discomfort: Baseline — Severe problems2
Pain / Discomfort: Baseline — Extreme problems0
Pain / Discomfort: Week 4 — No problems13
Pain / Discomfort: Week 4 — Slight problems4
Pain / Discomfort: Week 4 — Moderate problems6
Pain / Discomfort: Week 4 — Severe problems1
Pain / Discomfort: Week 4 — Extreme problems0
Pain / Discomfort: Month 3 — No problems8
Pain / Discomfort: Month 3 — Slight problems4
Pain / Discomfort: Month 3 — Moderate problems7
Pain / Discomfort: Month 3 — Severe problems2
Pain / Discomfort: Month 3 — Extreme problems0
Pain / Discomfort: Month 6 — No problems7
Pain / Discomfort: Month 6 — Slight problems6
Pain / Discomfort: Month 6 — Moderate problems5
Pain / Discomfort: Month 6 — Severe problems0
Pain / Discomfort: Month 6 — Extreme problems0
Anxiety / Depression: Baseline — No problems12
Anxiety / Depression: Baseline — Slight problems8
Anxiety / Depression: Baseline — Moderate problems4
Anxiety / Depression: Baseline — Severe problems0
Anxiety / Depression: Baseline — Extreme problems0
Anxiety / Depression: Week 4 — No problems14
Anxiety / Depression: Week 4 — Slight problems3
Anxiety / Depression: Week 4 — Moderate problems4
Anxiety / Depression: Week 4 — Severe problems2
Anxiety / Depression: Week 4 — Extreme problems1
Anxiety / Depression: Month 3 — No problems7
Anxiety / Depression: Month 3 — Slight problems9
Anxiety / Depression: Month 3 — Moderate problems3
Anxiety / Depression: Month 3 — Severe problems1
Anxiety / Depression: Month 3 — Extreme problems1
Anxiety / Depression: Month 6 — No problems11
Anxiety / Depression: Month 6 — Slight problems5
Anxiety / Depression: Month 6 — Moderate problems1
Anxiety / Depression: Month 6 — Severe problems1
Anxiety / Depression: Month 6 — Extreme problems0
SecondaryEQ-5D-5L Visual Analogue Scale (EQ-VAS) Score

The EQ-VAS is a vertical VAS for recording self-rated current Health-Related Quality of Life (HRQoL) state reported from 0, described as "the worst health you can imagine", to 100, described as "the best health you can imagine" Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).

Time frame:
Baseline, Week 4, Month 3, Month 6
Reported as:
Mean · score on a scale
EQ-5D-5L Visual Analogue Scale (EQ-VAS) Score
score on a scaleAxicabtagene Ciloleucel
Baseline76.6 ± 20.31
Week 475.8 ± 19.18
Month 379.8 ± 13.97
Month 682.5 ± 11.66
SecondaryPercentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

OR: complete response (complete metabolic response\[CMR\]; complete radiologic response\[CRR\]) or partial response (partial MR \[PMR\]; partial RR \[PRR\]). CMR: positron emission tomography(PET) 5-point scale(5-PS) of 1-3 with/without residual mass; no new sites/evidence of fluorodeoxyglucose(FDG)-avid disease in bone marrow(BM).CRR: target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter(LDi) of lesion;no extra lymphatic sites;absent nonmeasured lesion(NMLs);organ enlargement regress to normal;no new sites;BM normal by morphology.PMR:5PS scores 4/5 with reduced uptake compared to baseline,residual masses of any size;no new sites;residual uptake higher than uptake in normal BM,reduced compared with baseline.PRR:≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes \& extranodal sites;absent/normal,regressed but no increase of NMLs;spleen regressed by \>50%;no new sites of disease. 95% CI were calculated by Clopper-Pearson method.

Time frame:
Up to 2.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma93 (77.2 to 99.2)
SecondaryPercentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

Complete response is defined as participants with CMR and CRR. CMR: PET 5-PS scores of 1-3 with or without residual mass; no new sites/evidence of FDG-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5cm in LDi of lesion; no extra lymphatic sites; absent NMLs; organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% CI were calculated by Clopper-Pearson method. Percentages were rounded off.

Time frame:
Up to 2.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
percentage of participantsAxicabtagene Ciloleucel
Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma76 (56.5 to 89.7)
SecondaryDuration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

DOR is the time from first OR to disease progression (PD) or death from any cause. OR is defined in outcome measure (OM) 19. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

Time frame:
Up to 2.5 years
Reported as:
Median · months
Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
monthsAxicabtagene Ciloleucel
Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaNA (3.0 to NA)
SecondaryProgression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression or, if no disease progression, the date of death due to any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

Time frame:
Up to 2.5 years
Reported as:
Median · months
Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
monthsAxicabtagene Ciloleucel
Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaNA (3.8 to NA)
SecondaryEvent Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma

EFS is defined as the time from axicabtagene ciloleucel infusion to the earliest date of disease progression, commencement of new anti-lymphoma therapy (excluding SCT), or death from any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

Time frame:
Up to 2.5 years
Reported as:
Median · months
Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
monthsAxicabtagene Ciloleucel
Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaNA (3.8 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the axicabtagene ciloleucel infusion date to the date of death from any cause. KM estimates was used for analyses.

Time frame:
Up to 2.5 years
Reported as:
Median · months
Overall Survival (OS)
monthsAxicabtagene Ciloleucel
Overall Survival (OS)NA (NA to NA)
SecondaryPeak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15

Peak is defined as the maximum analyte level in blood measured after infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · picograms per milliliter (pg/mL)
Peak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
picograms per milliliter (pg/mL)Axicabtagene Ciloleucel
IL-227.15 (13.70 to 44.70)
IL-731.70 (27.60 to 42.40)
IL-1540.40 (29.00 to 58.00)
SecondaryPeak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · pg/mL
Peak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70
pg/mLAxicabtagene Ciloleucel
IFN-γ431.95 (173.10 to 1522.20)
IL-1NA (NA to NA)
IL-6211.00 (69.70 to 737.10)
IL-13NA (NA to NA)
IL-179.30 (9.30 to 27.55)
IL-1RA2033.50 (940.00 to 5457.00)
GM-CSF4.60 (1.90 to 9.60)
TNF-α4.35 (3.00 to 7.70)
IL-12p40160.50 (111.60 to 254.00)
IL-12p701.20 (1.20 to 1.20)
SecondaryPeak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · pg/mL
Peak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B
pg/mLAxicabtagene Ciloleucel
Granzyme A346.00 (270.00 to 478.00)
Granzyme B96.70 (56.60 to 147.00)
SecondaryPeak Serum Levels of Immune Effector Molecules: Perforin

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · nanograms per milliliter (ng/mL)
Peak Serum Levels of Immune Effector Molecules: Perforin
nanograms per milliliter (ng/mL)Axicabtagene Ciloleucel
Peak Serum Levels of Immune Effector Molecules: Perforin8.81 (5.78 to 16.38)
SecondaryPeak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · pg/mL
Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)
pg/mLAxicabtagene Ciloleucel
Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)817000000 (308000000 to 1380000000)
SecondaryPeak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · milligrams per liter (mg/L)
Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)
milligrams per liter (mg/L)Axicabtagene Ciloleucel
Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)115.44 (67.47 to 409.41)
SecondaryPeak Serum Levels of the Acute Phase Response Proteins: Ferritin

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · ng/mL
Peak Serum Levels of the Acute Phase Response Proteins: Ferritin
ng/mLAxicabtagene Ciloleucel
Peak Serum Levels of the Acute Phase Response Proteins: Ferritin997.87 (433.59 to 2535.89)
SecondaryPeak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · ng/mL
Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)
ng/mLAxicabtagene Ciloleucel
Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)11.67 (6.62 to 23.68)
SecondaryPeak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

Time frame:
From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Reported as:
Median · pg/mL
Peak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
pg/mLAxicabtagene Ciloleucel
IL-873.90 (34.10 to 205.60)
CXCL-102000.00 (1316.00 to 2000.00)
MCP-11251.00 (865.30 to 1500.00)
SecondaryPeak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells

Peak is defined as the maximum number of CAR T-cells in blood measured after axicabtagene ciloleucel infusion.

Time frame:
Up to 24 months
Reported as:
Median · cells per microliter (cells/μL)
Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells
cells per microliter (cells/μL)Axicabtagene Ciloleucel
Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells40.84 (30.54 to 68.89)

Adverse events

Collected over All-Cause Mortality: Up to 2.5 years; Adverse Events: Up to 2.2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axicabtagene Ciloleucel9/35 (25.7%)24/30 (80%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventAxicabtagene Ciloleucel
PyrexiaGeneral disorders18/30
Confusional statePsychiatric disorders6/30
Febrile neutropeniaBlood and lymphatic system disorders4/30
AphasiaNervous system disorders3/30
HypotensionVascular disorders3/30
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/30
Disseminated intravascular coagulationBlood and lymphatic system disorders1/30
ArrhythmiaCardiac disorders1/30
Large intestine perforationGastrointestinal disorders1/30
AstheniaGeneral disorders1/30
Most frequent other events
Showing 10 of 83
Most frequent other events
EventAxicabtagene Ciloleucel
HypotensionVascular disorders16/30
PyrexiaGeneral disorders14/30
ChillsGeneral disorders13/30
Neutrophil count decreasedInvestigations12/30
FatigueGeneral disorders11/30
Platelet count decreasedInvestigations11/30
HeadacheNervous system disorders11/30
White blood cell count decreasedInvestigations9/30
Confusional statePsychiatric disorders9/30
CoughRespiratory, thoracic and mediastinal disorders9/30

Baseline characteristics

The Safety Analysis Set included all participants who were treated with any dose of axicabtagene ciloleucel.

Age, Categorical
Age, Categorical(Participants)Axicabtagene Ciloleucel
<=18 years0
Between 18 and 65 years19
>=65 years11
Age, Continuous
Age, Continuous(years)Axicabtagene Ciloleucel
Mean60 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Axicabtagene Ciloleucel
Female10
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Axicabtagene Ciloleucel
Race — White22
Race — Asian3
Race — Black or African American2
Race — Other or More Than One Race1
Race — Not Collected2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Axicabtagene Ciloleucel
Ethnicity — Not Hispanic or Latino23
Ethnicity — Not Collected5
Ethnicity — Hispanic or Latino2
Region of Enrollment
Region of Enrollment(Participants)Axicabtagene Ciloleucel
United States30
08

Study locations

16 sites
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
    Duarte, California 91010, United States
  • UCLA
    Los Angeles, California 90025, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • University of Maryland Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Oncology Hematology Care Clinical Trials, LLC
    Cincinnati, Ohio 45242, United States
  • Prisma Health - Upstate
    Greenville, South Carolina 29615, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Methodist Healthcare System of San Antonio
    San Antonio, Texas 78229, United States
  • Intermountain Healthcare
    Murray, Utah 84107, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
09

References and documents

Publications

  • Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark W, Rapoport AP, Rodriguez TE, Winters JN, Davis M, Miao HM, Ray M, Fang X, Kim JJ, Oluwole OO. Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis. Am J Cancer Res. 2025 Aug 15;15(8):3417-3433. doi: 10.62347/GJNN1023. eCollection 2025. PubMed 40948517 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2025, 39 months.

Results were first posted in Nov 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2022
First posted
Jul 15, 2022
StartActual
Aug 9, 2022
Primary completionActual
Nov 24, 2025
CompletionActual
Nov 24, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedPercentage and Severity of Participants withWith Treatment-emergent Cytokine Release Syndrome (CRS) and Neurologic Eventsas Per SeverityTime frame: Up to 24 months → Up to 2.2 years
  • AddedPercentage of Participants With Treatment-emergent Neurologic Events as Per SeverityTime frame: Up to 2.2 years
Nov 12, 2026
Secondary outcomes
13 edited, 14 added, 3 removed, 12 more
What changed in the outcomes
  • EditedTime to Onset of CRS and Neurologic Events Following Axicabtagene Ciloleucel AdministrationTime frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
  • EditedDurationTime to Onset of CRS and Neurologic Events Following Axicabtagene Ciloleucel AdministrationTime frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
  • EditedProportionPercentage of Intensive Care Unit (ICU) Admitted ParticipantsTime frame: Up to 24 months → Up to 30 days
  • EditedPercentage of Participants Experiencing Treatment- Emergent Adverse Events (TEAEs)Time frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
  • EditedPercentage of Participants Experiencing Treatment- Emergent Serious Adverse Events (TESAEs)Time frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
  • EditedChange in theNumber of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) From Baseline to Month 6ScoreTime frame: Baseline, 6 Months → Baseline, Week 4, Month 3, Month 6
  • EditedDuration of responseResponse (DOR) as Assessed byAccording to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 24 months → Up to 2.5 years
  • EditedProgression-free Survival (PFS) as Assessed byAccording to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 24 months → Up to 2.5 years
  • EditedEvent Free Survival (EFS) as Assessed byAccording to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 24 months → Up to 2.5 years
  • EditedPeak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p40/p7012p70Time frame: Up to 24 months → From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • EditedPeak Serum Levels of Immune Effector Molecules: Granzyme A, and Granzyme B, and PerforinTime frame: Up to 24 months → From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • EditedPeak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP), Serum Amyloid A (SAA), Soluble IL-2 Receptor Alpha (sIL-1Ra), FerritinTime frame: Up to 24 months → From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • EditedPeak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells Over TimeTime frame: Up to 24 months
  • AddedDuration of CRS Following Axicabtagene Ciloleucel AdministrationTime frame: Up to 2.2 years
  • AddedDuration of Neurologic Events Following Axicabtagene Ciloleucel AdministrationTime frame: Up to 2.2 years
  • AddedPercentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel InfusionTime frame: Within 72 hours of axicabtagene ciloleucel infusion on Day 0
  • AddedPercentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
  • AddedPercentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
  • AddedPercentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
  • AddedPercentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
  • AddedEQ-5D-5L Visual Analogue Scale (EQ-VAS) ScoreTime frame: Baseline, Week 4, Month 3, Month 6
  • AddedPercentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 2.5 years
  • AddedPercentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 2.5 years
  • AddedPeak Serum Levels of Immune Effector Molecules: PerforinTime frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • AddedPeak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • AddedPeak Serum Levels of the Acute Phase Response Proteins: FerritinTime frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • AddedPeak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
  • RemovedRates of Hospitalization After Axicabtagene Ciloleucel Infusion as Measured by Proportion of Hospitalized Participants Within 72 hoursTime frame: First infusion date of axicabtagene ciloleucel up to 72 hours
  • RemovedRates of Hospitalization After Axicabtagene Ciloleucel Infusion as Measured by Proportion of Hospitalized Participants 3 Days After Infusion DateTime frame: First infusion date of axicabtagene ciloleucel up to 3 days
  • RemovedRates of Hospitalization After Axicabtagene Ciloleucel Infusion as Measured by Proportion of Hospitalized Participants Within 7 daysTime frame: First infusion date of axicabtagene ciloleucel up to 7 days
  • …and 12 more, on the record history on ClinicalTrials.gov ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedPercentage and Severity of Participants withWith Treatment-emergent Cytokine Release Syndrome (CRS) and Neurologic Eventsas Per SeverityTime frame: Up to 24 months → Up to 2.2 years
    • AddedPercentage of Participants With Treatment-emergent Neurologic Events as Per SeverityTime frame: Up to 2.2 years
    Secondary outcomes 13 edited, 14 added, 3 removed, 12 more
    What changed in the outcomes
    • EditedTime to Onset of CRS and Neurologic Events Following Axicabtagene Ciloleucel AdministrationTime frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
    • EditedDurationTime to Onset of CRS and Neurologic Events Following Axicabtagene Ciloleucel AdministrationTime frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
    • EditedProportionPercentage of Intensive Care Unit (ICU) Admitted ParticipantsTime frame: Up to 24 months → Up to 30 days
    • EditedPercentage of Participants Experiencing Treatment- Emergent Adverse Events (TEAEs)Time frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
    • EditedPercentage of Participants Experiencing Treatment- Emergent Serious Adverse Events (TESAEs)Time frame: First infusion date of axicabtagene ciloleucel up to 24 months → Up to 2.2 years
    • EditedChange in theNumber of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) From Baseline to Month 6ScoreTime frame: Baseline, 6 Months → Baseline, Week 4, Month 3, Month 6
    • EditedDuration of responseResponse (DOR) as Assessed byAccording to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 24 months → Up to 2.5 years
    • EditedProgression-free Survival (PFS) as Assessed byAccording to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 24 months → Up to 2.5 years
    • EditedEvent Free Survival (EFS) as Assessed byAccording to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 24 months → Up to 2.5 years
    • EditedPeak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p40/p7012p70Time frame: Up to 24 months → From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • EditedPeak Serum Levels of Immune Effector Molecules: Granzyme A, and Granzyme B, and PerforinTime frame: Up to 24 months → From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • EditedPeak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP), Serum Amyloid A (SAA), Soluble IL-2 Receptor Alpha (sIL-1Ra), FerritinTime frame: Up to 24 months → From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • EditedPeak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells Over TimeTime frame: Up to 24 months
    • AddedDuration of CRS Following Axicabtagene Ciloleucel AdministrationTime frame: Up to 2.2 years
    • AddedDuration of Neurologic Events Following Axicabtagene Ciloleucel AdministrationTime frame: Up to 2.2 years
    • AddedPercentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel InfusionTime frame: Within 72 hours of axicabtagene ciloleucel infusion on Day 0
    • AddedPercentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
    • AddedPercentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
    • AddedPercentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
    • AddedPercentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel InfusionTime frame: Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
    • AddedEQ-5D-5L Visual Analogue Scale (EQ-VAS) ScoreTime frame: Baseline, Week 4, Month 3, Month 6
    • AddedPercentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 2.5 years
    • AddedPercentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant LymphomaTime frame: Up to 2.5 years
    • AddedPeak Serum Levels of Immune Effector Molecules: PerforinTime frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • AddedPeak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • AddedPeak Serum Levels of the Acute Phase Response Proteins: FerritinTime frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • AddedPeak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
    • RemovedRates of Hospitalization After Axicabtagene Ciloleucel Infusion as Measured by Proportion of Hospitalized Participants Within 72 hoursTime frame: First infusion date of axicabtagene ciloleucel up to 72 hours
    • RemovedRates of Hospitalization After Axicabtagene Ciloleucel Infusion as Measured by Proportion of Hospitalized Participants 3 Days After Infusion DateTime frame: First infusion date of axicabtagene ciloleucel up to 3 days
    • RemovedRates of Hospitalization After Axicabtagene Ciloleucel Infusion as Measured by Proportion of Hospitalized Participants Within 7 daysTime frame: First infusion date of axicabtagene ciloleucel up to 7 days
    • …and 12 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05459571
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Aug 9, 2022
Primary completion
Nov 24, 2025
Completion
Nov 24, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axicabtagene ciloleucel

Start the discussion